ADVM - חוב כולל להון Adverum Biotechnologies, Inc.

The absence of revenue and the costs associated with the final stages of gene therapy trials are creating financial pressure for Adverum Biotechnologies (ADVM). However, the development of a one-time vision restoration method could provide the company with exceptional profits. Market price visualization on GURU.Markets shows that the total debt-to-equity ratio is 0.00, while management has effectively optimized expenses and maintains transparency regarding the progress of its developments.

This metric measures the degree of business reliance on borrowed funds relative to equity, highlighting debt service risks amid interest rate volatility. By analyzing the financial stability ratio (debt-to-equity), an investor assesses the ability of Adverum Biotechnologies (ADVM) to finance costly gene therapy developments for the treatment of ocular pathologies without imposing a critical debt burden on its high-tech capital.